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It has recently been demonstrated that mouse and human dendritic cells (DCs) can produce IL-2 after activation. However the
role of the IL2/IL2R pathway in DC functions has not yet been fully elucidated. The results presented in this study provide several
new insights into the role of this pathway in DCs. We report that stimulationof human monocyte-derived DCs with LPS strongly
upregulated CD25 (α chain of the IL2R) expression. In additon, by using a humanized monoclonal antibody against CD25, we
demonstrated that the IL2 signalling in DC upregulated both IL-12 and γIFN production but decreased IL10 synthesis. We also
foundthatLPS-maturedDCsproduced IL2.Takentogether, theseresultssuggestthatIL-2actively contributes totheDCactivation
through an autocrine pathway. Furthermore, our results indicate that the IL2 pathway in DC is involved in the development of
T-helper priming ability and in the upregulation of surface markers characteristic of a “mature” phenotype. This study therefore
provide new molecular clues regarding the split between these two phenomena and unravel new mechanisms of action of anti-
CD25 monoclonalantibodies that may contribute to their action in severalhuman immunologicaldisorders such as autoimmune
diseases and acute allograft rejection.
Dendritic cells (DCs) are bone-marrow-derived cells that
populate all lymphoid organs as well as nearly all non-
lymphoid organs. Although DCs display a heterogeneous
group of cells that represent diﬀerences in origin, anatomic,
location, cell surface phenotype, and function. They are
powerful antigen-presenting cells that have a critical role in
the initial activation of na¨ ıve cells and the recall of memory
immune responses.
Immature DCs reside as sentinels in non lymphoid
organs; they are high adapted for the uptake of antigen via
receptor- and nonreceptor-mediated mechanisms and read-
ily degrade antigens in endocytic vesicles to produce antigen
peptides capable of binding to Human Leukocyte Antigens
class II.
Upon maturation with pathogens, activated T Lympho-
cytes and/or inﬂammatory signals such as TNFα,I L - 1 β,o r
lipopolysaccharides (LPS), immature DCs underwent genet-
ic reprogramming leading to mature DCs characterized by
high expression of HLA class II molecules absence of lineage
m a r k e r ss u c ha sC D 1 4( m o n o c y t e s ) ,C D 3( Tc e l l s ) ,C D 1 9 ,
CD20 (B cells), CD56 (NK cells), high level expression of
costimulatory molecules CD83, CD86, CD80, CD40, and
adhesion moleculessuch as CD11a,CD11c.MatureDCsalso
acquire ability to migrate which is regulated by expression of
chemokines and chemokines receptors CCR7.
These chemokines guide mature DCs to lymphatic ves-
sels and to secondary lymphoid organs.
DC Subsets. In human DCs comprise at least three distinct
subsets.
(i) Langerhans cells LC and interstitial DCs belonging to
the myeloid lineage and plasmacytoid DCs originate
from a lymphoid precursor (Table 1).
(ii) LCs are localized in the layers of the epidermis in
the skin and other mucosal areas, whereas interstitial
DCsare present in the dermis of the skin and in most
other organs.
(iii) Human plasmacytoid DCs are found in the T-cell
zones of lymphoid organs (Table 1).
There seem to be several pathways to generate DCs.2 ISRN Pharmacology
Table 1
Postulated lineage Lymphoid Myeloid
DC subtype Plasmacytoid DC Interstitial DC Langerhans cell
Fully diﬀerentiated DC
CD11c− CD123+ CD11c+ CD123− CD11c+ CD123−
CD11b− CD13− CD33− CD11b+ CD13+ CD33+ CD11b+ CD13+ CD33+
CD1a− CD1a− CD1a+
Localization T-cell zones of lymphoid
organs
T-cell zones of lymphoid
organs immature cells in
peripheral tissues
T-cell zones of lymphoid
organs immature cells in
epithelia
Function
(i) Mannosereceptor-mediated endocytosis — +++ —
(ii) IL-12 +++ +++ +++
(iii) Il-10 — +++ —
(iv) IFNγ +++ — —
(v) CD4+ T-cell priming +++ +++ +++
Generation of dendritic cells
Monocytes
Immature dendritic
cells
Mature dendritic
cells
RPMI
10%
SVF
5d a y s
2d a y s
D0
D5
D7
IL-4 25ng/mL
GM-CSF 1000U/mL
IL-4 + GM-CSF
TNFα 20ng/mL
LPS 10U/mL
Figure 1: Protocol of dendritic cell generation.
BloodmonocytesgiverisetoDCswhenculturedwiththe
appropriate cytokines. DCs progenitors are also present in
bone marrow. CD34+ subsets of haematopoietic progenitors
give rise to all blood cells and DCs.
In vitro human DCs can be generated from CD34+ bone
marrow and peripheral blood progenitor’s cells: after culture
with diﬀerent cytokine combinations including GM-CSF,
TNFα,CD40L.Alternatively,DCcanbederivedfromCD14+
peripheral blood adhering monocytes.
PBMCs are obtained by cytapheresis isolated by Ficoll
Hypaque density gradient and cultured with GM-CSF and
rhIL-4. At the end of 5-days culture, immature DCs are
harvested. Maturation was induced by adding proinﬂamma-
tory stimuli such as TNFα,L P S ,o rI L - 1 β or on ligation of
CD40. At the last 48 h of culture on day 7, mature DCs were
harvested (Figure 1).
Upon maturation, DCs display high expression of
costimulatory, presenting and accessory molecules, uptake
molecules were decreased. Induction of allogeneic T-cell
proliferation in MLR by DCs has been associated with
DC maturation including production of proinﬂammatory
c y t o k i n e ss u c ha sT N F α, IL-12, IFNδ. Alternatively, DCs
produce low levels of IL-10, anti-inﬂammatory cytokine.
Recently, it has been reported that upon activation DCs
exhibit transient production of IL-2 and express IL-2Rα,a
propertythatappearstoberelatedtotheircapacitytoinitiate
immune responses. Besides, the ability of DCs to produce
IL-2 after encountering inﬂammatory stimuli provides theISRN Pharmacology 3
ﬁrst crucial signals for the activation of na¨ ıve T cells. The
kinetics of IL-2 production by DCs are compatible with the
appearance of HLA class II and class I peptides at the cell
surfaceofDCs,soIL-2appearstobeoneofthekeymolecules
conferring unique T-cell stimulating capacity on DCs.
Dendritic cells (DCs) play a key role in the initiation and
regulation of both the adaptative and the innate immune
responses [1–5]. DC progenitors leave the bone marrow
(BM) and give rise to circulating precursors. They diﬀer-
entiate into immature DCs that are distributed throughout
the peripheral tissues and mucosa and act as sentinels of
the immune system [3, 4]. They are characterized by a high
capacity for antigen uptake and processing [3]. In response
to inﬂammatory stimuli, immature DCs rapidly undergo a
complete genetic reprogramming. During the ﬁrst twenty-
four hours, DCs experience all the transcription modiﬁ-
cations necessary to progress from immature to mature
cells that are characterized by a high capacity for antigen
presentationand T-cell priming [5, 6] .T h em a t u r eD C st h e n
migrate to the secondary lymphoid organs where they inter-
act with T cells. This complex “maturation” process involves
not only the upregulation of costimulatory surface proteins
and the optimization of antigen presentation capacities, but
also the production of cytokines and chemokines [4–6]t h a t
profoundly inﬂuences the outcome of the T-cell response.
The signals in DC involved in each of these phenomena are
not completely understood.
The signals delivered by DC are believed to direct the T-
cell response into either a Th1, Th2, or nonpolarized T-cell
response [7, 8], but they can also drive the diﬀerentiation
of regulatory T cells involved in self-tolerance [2–9]. Thus,
the extraordinary versatility of dendritic cells has recently
become apparent. Although much is known about the
cytokines produced by T cells and the T-cell-associated tran-
scription factors that determine the T-helper polarization,
the early “decision-making mechanisms” which result in
a given type of immune response are poorly understood
a n dp o s s i b l ya r eb a s e do ns p e c i ﬁ cc y t o k i n ea n dc h e m o k i n e
synthesis proﬁles by DC. This area remains a subject of
intense investigations.
In addition to aﬀecting adaptative immunity, the cytoki-
ne synthesis proﬁles of DCs might also inﬂuence their capac-
ity to activate cells involved in innate immunity such as NK
cells [10, 11].
Ithasrecentlybeendemonstratedthatmouseandhuman
DCscanbothproduceIL-2afteractivationwithseveralstim-
uli [12]. The expression and the function of the IL2 receptor
on DCs have been rarely studied. One study in mice showed
IL-2RαexpressiononDCsbuttheycouldnotascribeanyrole
to its expression [13]. Thus, the role of IL2 signalling in DC
function remains poorly deﬁned. It was, therefore, relevant
to study how this pathway inﬂuenced the DC cytokine secre-
tion proﬁle and their ability to activate CD4+T cells.
In the present study, we report that CD25 expression was
strongly upregulated on DCs by several maturation signals
suchasLPS.Inaddition,we demonstratedthatIL2signalling
in DCs upregulated both IL-12 and IFNγ production but
decreased IL10 synthesis. We also found that LPS-matured
DCs produced IL2. Taken together, these results suggest
that IL-2 actively contributes to DC activation through an
autocrine pathway. Finally, our results indicate that the IL2
pathway in DC is involved in the development of T-helper
priming ability and in the upregulation of surface markers
characteristic of a “mature” phenotype. Antagonizing IL2
signalling in DCs may therefore inﬂuence the immune re-
sponse invivo. These actions of anti-CD25antibodies on DC
functions may contribute to their action in vivo on several
immunological disorders such as autoimmune diseases [14,
15] and prevention of acute human allograft rejection [16].
In conclusion, our data suggested that the level of IL2
signalling in DCs regulate their capacity to eﬃciently prime
the T-helper immune response. Therefore, targeting this
pathway ex vivo might be useful for protocols in cellular
therapy to orientate DC toward a tolerogenic proﬁle (by
using antiCD25 treated DC) able to promote Treg differenti-
ation or at the opposite to promote or restore immunity
against tumors (by using IL2-treated DCs).
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